A 38-year-old woman from rural India undergoes cervical screening and is found to have CIN-2 (cervical intraepithelial neoplasia grade 2) on colposcopy-directed biopsy. Regarding the natural history and management of CIN lesions, all of the following are correct EXCEPT:

Explanation

## Natural History and Management of Cervical Intraepithelial Neoplasia (CIN) ### Grading and Spontaneous Regression Rates **Key Point:** The natural history of CIN is grade-dependent: - **CIN-1 (mild dysplasia):** 60–90% spontaneous regression within 1–2 years in immunocompetent women; only 5–10% progress to CIN-3 or cancer. - **CIN-2 (moderate dysplasia):** Intermediate risk; ~40–50% regress, ~30–40% persist, and ~20–30% progress to CIN-3 or cancer. - **CIN-3 (severe dysplasia/carcinoma in situ):** High risk of progression (30–50% to invasive cancer within 10 years if untreated); minimal spontaneous regression. ### Role of Persistent HPV Infection **High-Yield:** Persistent infection with high-risk HPV types (HPV-16, HPV-18, HPV-31, HPV-33, HPV-45) is the essential driver of progression from CIN to invasive cervical cancer. Clearance of HPV infection is associated with regression of CIN lesions. Transient HPV infections are typically cleared by the immune system within 6–24 months without causing significant disease. ### Management of CIN-2 **Clinical Pearl:** CIN-2 is considered a precancerous lesion with significant malignant potential and should be treated. Recommended management includes: - **Excisional procedures:** Loop electrosurgical excision procedure (LEEP), cold-knife conization, or laser conization. - **Goal:** Complete removal with negative margins to reduce recurrence risk. - **Follow-up:** HPV testing or cytology at 6 months and annually for at least 25 years. ### Progression Rates: The Critical Distinction **Warning:** The risk of progression from **CIN-1** to invasive cancer within 5 years is approximately **5–10%**, NOT 50%. The 50% figure is often confused with the progression rate from **CIN-3** to invasive cancer over 10 years. CIN-1 has a much lower malignant potential; most CIN-1 lesions regress spontaneously. ### Summary Table: CIN Natural History | CIN Grade | Spontaneous Regression | Persistence | Progression to Cancer | Management | |-----------|------------------------|-------------|----------------------|-------------| | CIN-1 | 60–90% | 5–10% | 5–10% (5 years) | Observation or HPV testing; treat if persistent | | CIN-2 | 40–50% | 30–40% | 20–30% (5 years) | **Excisional treatment** | | CIN-3 | <5% | 10–20% | 30–50% (10 years) | **Excisional treatment** | **Mnemonic:** **"CIN-1 = Chill, CIN-3 = Concern"** — CIN-1 often regresses; CIN-3 requires aggressive management. [cite:Robbins 10e Ch 7; Park 26e Ch 3]